Effects of nilotinib on regulatory T cells: the dose matters
Fei Fei(University of Southern California), Michael Schmitt(German Cancer Research Center)
Cited by 29
Related Papers
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
|Nature Medicine|2023|226
Nilotinib hampers the proliferation and function of CD8<sup>+</sup> T lymphocytes through inhibition of T cell receptor signalling
|Journal of Cellular and Molecular Medicine|2008|78
Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias
|Molecular Cancer Therapeutics|2010|37